Navigation Links
New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Date:3/31/2008

Data expands body of evidence in high risk population using IVUS, a unique

marker for coronary atherosclerosis

CHICAGO, March 31 /PRNewswire/ -- New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS(R) (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline. These data stem from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial.

The PERISCOPE trial was presented today as a late breaker at the 57th Annual Scientific Session of the American College of Cardiology in Chicago. This trial adds to the body of cardiovascular data for ACTOS. ACTOS studies, conducted over the past 10 years in more than 16,000 patients, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

"We are pleased with the results of the PERISCOPE, which further expands our cardiovascular data with ACTOS," said David P. Recker, M.D., senior vice president, Clinical Sciences and interim president at Takeda Global Research & Development. "While not definitive, data from PERISCOPE combined with results from a previous study, looking at surrogate endpoints, have shown a consistent trend toward decreasing cardiovascular risk by reducing the atherosclerotic burden in people with type 2 diabetes."

PERISCOPE is the first clinical trial to examine the effects of an oral antidiabetic medication on the development of coronary atherosclerosis in patients with type 2 diabetes using IVUS technology. The trial conducted in 97 centers in the U.S., Canada and Latin America with 543 patients, used IVUS imaging of the coronary arteries. The analysis demonstrated a statisticall
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
2. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
3. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
4. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
5. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
6. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
7. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
10. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
11. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Newport Corporation (NASDAQ: ... has joined the company,s Board of Directors.  Dr. ... a director of Evans Analytical Group, a leading ... analytical services to companies in a wide range ... Evans Analytical Group, Dr. Kadia spent nine years ...
(Date:12/19/2014)... Breckenridge Pharmaceutical, Inc. announced today that it ... Pvt. Ltd. ( Hyderabad, India ) under ... ANDAs.  Under the terms of the agreement, MSN will ... for the U.S. market, and Breckenridge will market and ... have agreed to develop an oral antibiotic with current ...
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... marketplace, innovative consumer research and marketing communication tools ... rich and globally competitive – consequently consumers, desires, ... In this environment, market research groups across ... research and marketing communication tools. However, the adoption ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
... Bionovo, Inc. (NASDAQ: BNVI ), a pharmaceutical company ... treatments for women,s health and cancer, today announced it will ... their lead drug candidate for postmenopausal symptoms, Menerba ™ ... 13th Annual World Congress on Menopause in Rome, Italy on ...
... Inc. (Nasdaq: ISIS ), the leader in antisense ... at Jefferies, 2011 Global Healthcare Conference on Thursday, June 09, ... York. A live audio webcast of the presentation ... the Company,s Web site, www.isispharm.com .  A replay of ...
Cached Medicine Technology:Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause 2Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause 3Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause 4
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... December 19, 2014 SuperCloset raises the ... Rooms. SuperCloset continues to offer indoor growers the most ... of the new SuperClone Rooms with the award winning ... turnkey indoor hydroponic grow room setup. , The SuperClone ... SuperCloset’s SuperPonic SuperCloner 50 . The ...
(Date:12/19/2014)... An evening dress is perfect for any occasion and ... distinguished dresses retailer, has unveiled its new selection of evening ... great shopping platform. Customers can view more at ... has been accepted and praised by customers for many years. ... for clients. In order to expand its market share, the ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- New research warns parents that ... lives at risk. Nearly half of teen drivers killed in ... were at least 11 years old and often lacked important safety ... Eighty-two percent of teen drivers killed in crashes were in cars ... to 10 years old, 31 percent were in cars 11 to ...
(Date:12/19/2014)... Potentially illness-causing E. coli bacteria were found on nearly ... a new study. Researchers checked cilantro, basil and ... in Los Angeles and Orange counties in California, and ... tested, 24 percent were positive for E. coli. One ... Both types of bacteria can cause sometimes serious ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... In an effort to extend the length of a ... Baptist Medical Center are partnering with colleagues from across the ... by the US National Institute on Aging (NIA). ... aims to assess whether aspirin can not only prolong life, ...
... HealthDay Reporter , WEDNESDAY, July 7 (HealthDay News) ... cancer is less accurate when done in the summer than ... Although the particular brand of test used in the ... the United States, the findings are of interest to U.S. ...
... ... FDA reports of the shocking conditions in manufacturing plants have pediatricians and parents concerned ... ... the year there have been numerous recalls of infants’ and children’s over-the-counter (OTC) pharmaceutical ...
... detection today is X-ray mammography, which takes images of ... are several disadvantages to using X-rays for breast cancer ... and the high costs, which limit their wide use ... depending on the age of the patient and tissue ...
... D.C. (July 1, 2010) -- Thousands of scientists and ... meet at the 52nd meeting of the American Association ... 22, 2010 in Philadelphia, Pennsylvania. They will present the ... and discuss the safety and regulatory issues facing the ...
... , WEDNESDAY, July 7 (HealthDay News) -- ... chronic low back pain influence how they manage their ... ability to find, understand and use health information. Low ... in many chronic conditions, but this relationship has not ...
Cached Medicine News:Health News:Can aspirin prolong a healthy life? 2Health News:Could Hot Weather Affect Results of a Colorectal Cancer Test? 2Health News:Could Hot Weather Affect Results of a Colorectal Cancer Test? 3Health News:Could Hot Weather Affect Results of a Colorectal Cancer Test? 4Health News:Safety in Children's Pain Relief Products a Primary Concern 2Health News:Safety in Children's Pain Relief Products a Primary Concern 3Health News:Mathematical models for breast cancer detection with microwave tomography are cheaper and less risky 2Health News:Understanding Back Pain May Improve Management, Study Suggests 2
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications....
The VersaFluor cuvette fluorometer is a fast and simple way to quantitate DNA, RNA, and proteins, to detect apoptosis, and to perform reporter enzyme assays with the high level of sensitivity and sel...
... unique microprocessor-controlled filter wheels for wavelength selection ... filter wheels can be programmed for excitation ... With this fluorometer, you do not have ... wavelengths. The C&L Dye Fluorometer can measure ...
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
Medicine Products: